Harvard Bioscience, Inc. (HBIO)

Market Cap	123.31M
Revenue (ttm)	117.96M
Net Income (ttm)	-6.89M
Shares Out	41.66M
EPS (ttm)	-0.17
PE Ratio	n/a
Forward PE	14.93
Dividend	n/a
Ex-Dividend Date	n/a

Volume	47,107
Open	2.89
Previous Close	2.87
Day's Range	2.83 - 3.00
52-Week Range	1.98 - 6.49
Beta	1.54
Analysts	Buy
Price Target	3.98 (+34.46%)
Earnings Date	Mar 14, 2023

About HBIO

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate rea...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• CEO: Mr. James W. Green
• Employees: 475
• Stock Exchange: NASDAQ
• Ticker Symbol: HBIO

Financial Performance

In 2021, HBIO's revenue was $118.90 million, an increase of 16.46% compared to the previous year's $102.10 million. Losses were -$288,000, -96.31% less than in 2020.

Analyst Forecast

According to 9 analysts, the average rating for HBIO stock is "Buy." The 12-month stock price forecast is $3.98, which is an increase of 34.46% from the latest price.

Price Target

$3.98

(34.46% upside)

Analyst Consensus: Buy